Get started
Work

Lisocabtagene Maraleucel (liso‐cel) Versus Standard of Care (soc) as Second‐line Therapy in Large B‐cell Lymphoma (transform Study): Subgroup Analyses by Prior Therapy Response

Year: 2023
Type: article
Abstract: Introduction: Over half of relapsed/refractory large B-cell lymphoma (rrLBCL) patients receiving anti-CD19 chimeric antigen receptor (CAR19) T-cells experience subsequent relapse.Improved methods
DOI: 10.1002/hon.3163_138
Authors: L. J. Nastoupil, M. Kamdar, J. C. Chavez, H. Ghesquieres, M. Ghosh, H. Holmes, A. López‐Guillermo, J. Martínez‐López, U. Novak, V. Ribrag, C. Roddie, E. K. Waller, T. Feldman, A. C. Rosenthal, C. Sauter, M. von Bonin, R. Karmali, S. Montheard, A. Previtali, J. Abramson
Institutions: The University of Texas MD Anderson Cancer Center, University of Colorado Cancer Center, Moffitt Cancer Center, Hôpital Lyon Sud, Michigan Medicine, Hospital Clínic de Barcelona, Hospital Universitario 12 De Octubre, University Hospital of Bern, Institut Gustave Roussy, University College London, Emory University, Winship Cancer Institute, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack Meridian School of Medicine, Mayo Clinic, Mayo Clinic Hospital, Memorial Sloan Kettering Cancer Center, University Hospital Carl Gustav Carus, Northwestern University, Bristol-Myers Squibb (Switzerland), Harvard University, Massachusetts General Hospital
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4379979624
FWCI: 0.104
Cites:
Cited by: 1
Related to: 10